Visit Ingenuity Systems at booth 307 at Molecular Medicine 2011 to learn about new features in IPA 9.0, including support for microRNA and RNA-Seq workflows. Ingenuity scientists will also be speaking about microRNA research at 12:30 pm on 2/24 (in the Molecular Diagnostics track) and presenting a poster on using RNA-Seq data in IPA.
Molecular Medicine is fast approaching, and here at Ingenuity, we’re really excited. It’s the first chance we’ve had to showcase some of the new features in the upcoming release of IPA 9.0. There are three new features we’ll be introducing at Molecular Medicine:
- microRNA Target Filter and microRNA content – Now you can reduce the number of steps it takes to confidently identify relevant microRNA targets by examining microRNA-mRNA pairings (from TargetScan and TarBase), exploring the related biological context of these relationships, and filtering mRNA targets based on relevant biological characteristics, all within a single tool.
- Support for RNA-Seq workflows – Upload processed RNA-Seq datasets directly into IPA. This lets you analyze and interpret your RNA-Seq data in the context of known biology, for a more comprehensive view of your experimental system.
- Enhanced user interface – IPA’s new graphical user interface supports a more intuitive user interaction and streamlined access to a variety of important workflows. It also enables you to upload and analyze your data in one simple step, more quickly search for genes or pathways, and more easily visualize connections among genes.
Sound interesting? Stop by Booth 307 to learn more about the upcoming release (plus, we’re giving away airline vouchers)! Here’s where else you can find us at Molecular Medicine to learn more:
Presentation: “Using IPA to explore microRNA impacts on molecular mechanisms of disease”
Thursday, 2/24, 12:30 pm – Molecular Diagnostics Track, Room 135
Dr. Dana Abramovitz, Product Manager at Ingenuity, will discuss how unique new features in IPA support a powerful microRNA workflow that can help researchers rapidly identify biologically relevant microRNA targets and related mechanisms.
Abstract: In the rapidly evolving field of microRNA research, which still relies heavily on a variety of measurement techniques and prediction algorithms for target identification, the challenge is in identifying the most biologically relevant targets. In a study to identify potential microRNA markers for disease progression from primary melanoma to metastatic melanoma, we used the approach of applying biological information to help prioritize mRNA targets, understand how these biomarker candidates contribute to disease progression, and design follow-up experiments to test our hypotheses. IPA’s new microRNA Target Filter functionality enables prioritization of experimentally validated and predicted mRNA targets through the addition of biological information from the Ingenuity Knowledge Base and the ability to include experimental results in a single application.
Poster: “Integrated in silico analysis of NGS prostate cancer data via high-resolution RNA-Seq analysis.”
Poster times: Wednesday 2/23 – Thursday 2/24
Dr. Antoaneta Vladimirova, Scientific Manager at Ingenuity, will be present to discuss how IPA can provide richer biological insights from RNA-Seq data and accelerate the identification of biomarkers and therapeutic targets.
Abstract: Prostate adenocarcinoma is the most frequent carcinoma in men and the second leading cause of death in the male population worldwide. The goal of our study was to get novel insights into the mechanisms of the disease by leveraging the rapidly growing next generation sequencing (NGS) data, and in particular, human transcriptome data through in silico data analysis and interpretation. The analysis of altered expression of genes and regulatory regions can pinpoint specific pathways and processes activated in growing cancer cells within tumors. Determining these activated pathways and networks can shed light on dysregulated processes, inform treatment options and highlight potential biomarkers with the ultimate goal to improve patient prognosis and treatment. High-resolution technologies, such as RNA-Seq, generate data that can be used to interrogate patient samples for expression changes and their patterns. Using short read RNA-Seq data from the NCBI SRA (Short Read Archive) public repository, gene expression changes from human prostate tumor and matched normal patient samples were assessed using CLC Genomics Workbench and CLC Genomics Server. To elucidate the underlying dysregulated biological processes, in silico pathway and mechanistic analysis was conducted in Ingenuity’s IPA software application by leveraging manually-curated biological information, canonical pathways and a variety of analytical tools. This poster highlights some of the results of this integrated in silico analysis and introduces a proposed workflow for the analysis and interpretation of RNA-Seq data.
We hope you stop by to introduce yourself. We’ll have Ingenuity team members from the support, sales, and science sides, all eager to answer your questions about data analysis and let you know more about how IPA can help. Plus, we’ll also be giving away airline vouchers at our booth, so stop by and enter to win!
Questions? Email email@example.com.
See you in San Francisco!